A
Albert Lai
Researcher at University of California, Los Angeles
Publications - 289
Citations - 13635
Albert Lai is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 59, co-authored 253 publications receiving 11888 citations. Previous affiliations of Albert Lai include Salk Institute for Biological Studies & Columbia University.
Papers
More filters
Journal ArticleDOI
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
Timothy F. Cloughesy,Koji Yoshimoto,Phioanh L. Nghiemphu,Kevin M. Brown,Julie Dang,Shaojun Zhu,Teli Hsueh,Yinan Chen,Wei-wei Wang,David Youngkin,Linda M. Liau,Neil A. Martin,Don Becker,Marvin Bergsneider,Albert Lai,Richard M. Green,Tom Oglesby,Michael Koleto,Jeff Trent,Steve Horvath,Paul S. Mischel,Ingo K. Mellinghoff,Charles L. Sawyers +22 more
TL;DR: Rapamycin has anticancer activity in PTEN-deficient glioblastoma and warrants further clinical study alone or in combination with PI3K pathway inhibitors.
Journal ArticleDOI
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai,Anh Tran,Phioanh L. Nghiemphu,Whitney B. Pope,Orestes E. Solis,Michael T. Selch,Emese Filka,William H. Yong,Paul S. Mischel,Linda M. Liau,Surasak Phuphanich,Keith L. Black,Scott Peak,Richard M. Green,Cynthia E. Spier,Tatjana Kolevska,Jonathan Polikoff,Louis Fehrenbacher,Robert Elashoff,Timothy F. Cloughesy +19 more
TL;DR: Comparative subset analysis showed that poor prognosis patients (recursive partitioning analysis class V/VI) may derive an early benefit from the use of first-line BV and TMZ during and after RT showed improved PFS without improved OS compared to the University of California, Los Angeles/KPLA control group.
Journal ArticleDOI
A review of approaches to identifying patient phenotype cohorts using electronic health records
Chaitanya Shivade,Preethi Raghavan,Eric Fosler-Lussier,Peter J. Embi,Noémie Elhadad,Stephen B. Johnson,Albert Lai +6 more
TL;DR: There are a variety of approaches for classifying patients into a particular phenotype, and good performance is reported on datasets at respective institutions, however, no system makes comprehensive use of electronic medical records addressing all of their known weaknesses.
Journal ArticleDOI
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Albert Lai,Samir Kharbanda,Whitney B. Pope,Anh Tran,Orestes E. Solis,Franklin Peale,William F. Forrest,Kanan Pujara,Jose Carrillo,Ajay Pandita,Benjamin M. Ellingson,Chauncey W. Bowers,Robert Soriano,Nils Ole Schmidt,Sankar Mohan,William H. Yong,Somasekar Seshagiri,Zora Modrusan,Zhaoshi Jiang,Kenneth Aldape,Paul S. Mischel,Linda M. Liau,Cameron Escovedo,Weidong Chen,Phioanh L. Nghiemphu,C. David James,Michael D. Prados,Manfred Westphal,Katrin Lamszus,Timothy F. Cloughesy,Heidi S. Phillips,Heidi S. Phillips +31 more
TL;DR: Although histologically similar, GBMs arising with and without IDH1(R132MUT) appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events.
Journal ArticleDOI
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
Wei Chen,Sibylle Delaloye,Daniel H.S. Silverman,Cheri Geist,Johannes Czernin,James Sayre,Nagichettiar Satyamurthy,Whitney B. Pope,Albert Lai,Michael E. Phelps,Timothy F. Cloughesy +10 more
TL;DR: FLT- PET as an imaging biomarker seems to be predictive of overall survival in bevacizumab and irinotecan treatment of recurrent gliomas, and whether FLT-PET performed as early as 1 to 2 week after starting treatment is as predictive as the study indicates at 6 weeks warrants further investigation.